[1] Chen W Q, Zheng R S, Baade P D, et al. Cancer statistics in China, 2015[J]. CA-A Cancer Journal for Clinicians, 2016, 66(2): 115-132. [2] Haider M A, van der Kwast T H, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer[J]. American Journal of Roentgenology, 2007, 189(2): 323-328. [3] Kumar V, Bora G S, Kumar R, et al. Multiparametric (mp) MRI of prostate cancer[J]. Progress in Nuclear Magnetic Resonance Spectroscopy, 2018, 105: 23-40. [4] Kozlowski P, Chang S D, Jones E C, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology[J]. Journal of Magnetic Resonance Imaging, 2006, 24(1): 108-113. [5] Auer T, Edlinger M, Bektic J, et al. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results[J]. World Journal of Urology, 2017, 35(5): 687-693. [6] Khalvati F, Wong A, Haider M A. Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models[J]. BMC Medical Imaging, 2015, 15: 27. [7] Ishioka J, Matsuoka Y, Uehara S, et al. Computer-aided diagnosis of prostate cancer on magnetic resonance imaging using a convolutional neural network algorithm[J]. BJU International, 2018, 122(3): 411-417. [8] Vignati A, Mazzetti S, Giannini V, et al. Texture features on T2-weighted magnetic resonance imaging: new potential biomarkers for prostate cancer aggressiveness[J]. Physics in Medicine and Biology, 2015, 60(7): 2685-2701. [9] Patel N, Henry A, Scarsbrook A. The value of MR textural analysis in prostate cancer[J]. Clinical Radiology, 2019, 74(11): 876-885. [10] Viswanath S E, Bloch N B, Chappelow J C, et al. Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 Tesla endorectal, in vivo T2-weighted MR imagery[J]. Journal of Magnetic Resonance Imaging, 2012, 36(1): 213-224. [11] Wibmer A, Hricak H, Gondo T, et al. Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores[J]. European Radiology, 2015, 25(10): 2840-2850. [12] Weinreb J C, Barentsz J O, Choyke P L, et al. PI-RADS prostate imaging-reporting and data system: 2015, version 2[J]. European Urology, 2016, 69(1): 16-40. [13] Chen T, Li M J, Gu Y F, et al. Prostate cancer differentiation and aggressiveness: Assessment with a radiomic-based model vs. PI-RADS v2[J]. Journal of Magnetic Resonance Imaging, 2019, 49(3): 875-884. [14] 居敏昊, 魏超刚, 陆志华, 等. 不同版本PI-RADS(v1与v2)对前列腺癌诊断的一致性分析[J]. 放射学实践, 2019, 34(10): 1132-1136. [15] 姬健智, 张 倩, 牛 猛, 等. 联合临床、MR T2WI及表观弥散系数图影像组学特征列线图预测初发前列腺癌骨转移[J]. 中国医学影像技术, 2022, 38(7): 1050-1055. [16] Giambelluca D, Cannella R, Vernuccio F, et al. PI-RADS 3 lesions: Role of prostate MRI texture analysis in the identification of prostate cancer[J]. Current Problems in Diagnostic Radiology, 2021, 50(2): 175-185. |